Subtopic Deep Dive
Chemokine Receptors as Cancer Therapeutics
Research Guide
What is Chemokine Receptors as Cancer Therapeutics?
Chemokine receptors as cancer therapeutics target receptors like CXCR4 and CCR5 with antagonists and antibodies to inhibit tumor metastasis and immune cell infiltration in oncology.
Clinical trials test CXCR4 antagonists such as plerixafor (AMD3100) for mobilizing stem cells in multiple myeloma and non-Hodgkin's lymphoma (Devine et al., 2004, 414 citations). Anti-CCR4 antibodies and CCL2-CCR2 inhibitors address solid tumors and metastasis (Lim et al., 2016, 510 citations). Over 10 key papers since 2004 document SDF-1/CXCL12-CXCR4 axis roles in cancer stem cell trafficking (Kucia et al., 2005, 754 citations).
Why It Matters
CXCR4 antagonists like AMD3100 rapidly mobilize CD34+ cells in lymphoma patients, enabling stem cell transplantation (Devine et al., 2004). CCL2-CCR2 blockade reduces monocyte recruitment to tumors, slowing metastasis in preclinical models (Lim et al., 2016). SDF-1/CXCR4 inhibition disrupts cancer stem cell homing to bone marrow, offering metastasis prevention in breast and prostate cancers (Kucia et al., 2005). CCR5 antagonists limit T-cell trafficking that promotes tumor progression (Aldinucci et al., 2020). These approaches improve survival in hematologic malignancies and predict responsiveness via biomarkers in metastatic solid tumors.
Key Research Challenges
Antagonist Specificity
CXCR4 antagonists like AMD3100 mobilize hematopoietic cells but risk off-target effects on normal stem cell trafficking (Eash et al., 2010). Balancing tumor inhibition with immune homeostasis remains unresolved (Burns et al., 2006).
Tumor Microenvironment Resistance
Tumor-associated macrophages polarized by CCL2-CCR2 signaling evade antagonists, sustaining progression (Hao et al., 2012). Neutrophil infiltration via CXCR2/CXCR4 axes promotes resistance (Vogt Sionov et al., 2014).
Biomarker Validation
Predicting patient response to CCR5/CCL5 inhibitors requires validated markers of receptor expression in metastases (Aldinucci et al., 2020). Clinical heterogeneity complicates trial endpoints (Kohli et al., 2021).
Essential Papers
A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development
Jennifer M. Burns, Bretton C. Summers, Yu Wang et al. · 2006 · The Journal of Experimental Medicine · 1.3K citations
The chemokine stromal cell–derived factor (SDF-1; also known as chemokine ligand 12 [CXCL12]) regulates many essential biological processes, including cardiac and neuronal development, stem cell mo...
Macrophages in Tumor Microenvironments and the Progression of Tumors
Ning-Bo Hao, Muhan Lü, Yahan Fan et al. · 2012 · Clinical and Developmental Immunology · 983 citations
Macrophages are widely distributed innate immune cells that play indispensable roles in the innate and adaptive immune response to pathogens and in-tissue homeostasis. Macrophages can be activated ...
CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow
Kyle J. Eash, Adam Greenbaum, Priya Gopalan et al. · 2010 · Journal of Clinical Investigation · 756 citations
Neutrophils are a major component of the innate immune response. Their homeostasis is maintained, in part, by the regulated release of neutrophils from the bone marrow. Constitutive expression of t...
Trafficking of Normal Stem Cells and Metastasis of Cancer Stem Cells Involve Similar Mechanisms: Pivotal Role of the SDF‐1–CXCR4 Axis
Magda Kucia, Ryan Reca, Katarzyna Miękus et al. · 2005 · Stem Cells · 754 citations
The alpha-chemokine stromal-derived factor (SDF)-1 and the G-protein-coupled seven-span transmembrane receptor CXCR4 axis regulates the trafficking of various cell types. In this review, we present...
Key chemokines direct migration of immune cells in solid tumors
Karan Kohli, Venu G. Pillarisetty, Teresa S. Kim · 2021 · Cancer Gene Therapy · 520 citations
Targeting the CCL2-CCR2 signaling axis in cancer metastasis
Su Yin Lim, Arseniy E. Yuzhalin, Alex Gordon‐Weeks et al. · 2016 · Oncotarget · 510 citations
The CCL2-CCR2 signaling axis has generated increasing interest in recent years due to its association with the progression of cancer. Although first described as a chemotactic molecule with physiol...
The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment
Ronit Vogt Sionov, Zvi G. Fridlender, Zvi Granot · 2014 · Cancer Microenvironment · 420 citations
Neutrophils are myeloid cells that constitute 50-70 % of all white blood cells in the human circulation. Traditionally, neutrophils are viewed as the first line of defense against infections and as...
Reading Guide
Foundational Papers
Burns et al. (2006) for CXCR7 discovery in tumor survival (1256 citations); Kucia et al. (2005) for SDF-1/CXCR4 in metastasis (754 citations); Devine et al. (2004) for AMD3100 clinical mobilization (414 citations)—establish core mechanisms and proof-of-concept.
Recent Advances
Aldinucci et al. (2020) on CCL5/CCR5 progression (382 citations); Kohli et al. (2021) on chemokines in solid tumors (520 citations); Lim et al. (2016) on CCL2-CCR2 metastasis (510 citations)—cover immune cell targeting advances.
Core Methods
CXCR4 antagonism with AMD3100 (Devine et al., 2004); CCL2-CCR2 signaling blockade (Lim et al., 2016); biomarker profiling via flow cytometry and qPCR for receptor expression (Aldinucci et al., 2020).
How PapersFlow Helps You Research Chemokine Receptors as Cancer Therapeutics
Discover & Search
Research Agent uses searchPapers for 'CXCR4 antagonists cancer trials' yielding Devine et al. (2004); citationGraph maps 414 downstream citations to plerixafor trials; findSimilarPapers links to Lim et al. (2016) on CCR2; exaSearch uncovers unpublished preprints on CCR4 antibodies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract trial data from Devine et al. (2004), verifyResponse with CoVe checks CXCR4 mobilization stats against Eash et al. (2010), runPythonAnalysis plots neutrophil trafficking curves from raw data with pandas/matplotlib, GRADE grades evidence as high for AMD3100 efficacy.
Synthesize & Write
Synthesis Agent detects gaps in CCR5 biomarker studies post-Aldinucci et al. (2020); Writing Agent uses latexEditText for review drafting, latexSyncCitations integrates 10 papers, latexCompile generates PDF, exportMermaid diagrams SDF-1/CXCR4 signaling pathways.
Use Cases
"Analyze CXCR4 antagonist trial data from multiple myeloma patients"
Research Agent → searchPapers 'AMD3100 multiple myeloma' → Analysis Agent → readPaperContent (Devine 2004) → runPythonAnalysis (pandas plot CD34+ mobilization vs time) → researcher gets statistical summary CSV with p-values.
"Draft LaTeX review on CCL2-CCR2 in metastasis"
Synthesis Agent → gap detection on Lim 2016 → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (10 papers) → latexCompile → researcher gets compiled PDF with figures.
"Find code for CXCR4 signaling simulations"
Research Agent → paperExtractUrls (Burns 2006) → paperFindGithubRepo → githubRepoInspect → researcher gets Python models of SDF-1 binding affinities.
Automated Workflows
Deep Research workflow scans 50+ papers on CXCR4 therapeutics via searchPapers → citationGraph → structured report with GRADE scores on trial outcomes. DeepScan applies 7-step CoVe to verify Kucia et al. (2005) metastasis claims against Burns et al. (2006). Theorizer generates hypotheses on combining CXCR4/CCR2 antagonists from Hao et al. (2012) and Lim et al. (2016).
Frequently Asked Questions
What defines chemokine receptors as cancer therapeutics?
Targeting GPCR receptors like CXCR4 with antagonists (plerixafor) and CCR4 with antibodies to block metastasis signaling (Devine et al., 2004).
What are key methods?
Small-molecule CXCR4 antagonists mobilize cells (Eash et al., 2010); monoclonal antibodies block CCR5/CCL5 (Aldinucci et al., 2020); biomarkers assess expression.
What are seminal papers?
Burns et al. (2006, 1256 citations) identifies CXCR7 in tumors; Kucia et al. (2005, 754 citations) links SDF-1/CXCR4 to metastasis; Devine et al. (2004, 414 citations) validates AMD3100 clinically.
What open problems exist?
Overcoming resistance from tumor macrophages (Hao et al., 2012); validating biomarkers for solid tumors (Kohli et al., 2021); reducing off-target stem cell effects (Eash et al., 2010).
Research Chemokine receptors and signaling with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Chemokine Receptors as Cancer Therapeutics with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Chemokine receptors and signaling Research Guide